Fate Therapeutics, Inc.

FATE

$1.61

Name : Fate Therapeutics, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $195,117,856.00

EPSttm : -1.03

Fate Therapeutics, Inc.

$1.61

9.32%

$0.165

FATE — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

8.6

Margin Of Safety %

Put/Call OI Ratio

0.36

EPS Next Q Diff

-0.03

EPS Last/This Y

0.13

EPS This/Next Y

0.05

Price

1.6

Target Price

5.56

Analyst Recom

2.09

Performance Q

-36.31

Upside

-931.7%

Beta

2.68

Ticker: FATE

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-13	FATE	2	0.18	0.40	6130
2026-10-14	FATE	1.94	0.18	0.06	6219
2026-10-15	FATE	1.93	0.17	0.00	6245
2026-10-16	FATE	1.78	0.17	0.00	6257
2026-10-19	FATE	1.87	0.19	0.33	5837
2026-10-20	FATE	2.06	0.19	4.53	5825
2026-10-21	FATE	2.08	0.20	1.46	5921
2026-10-22	FATE	2.105	0.21	2.13	6012
2026-10-23	FATE	2.11	0.20	4.94	6010
2026-10-26	FATE	2.05	0.20	3.46	5992
2026-10-27	FATE	2.07	0.21	17.80	6141
2026-10-28	FATE	2.17	0.22	0.76	6231
2026-10-29	FATE	2.18	0.24	1.34	6306
2026-10-30	FATE	2.09	0.24	0.76	6341
2026-11-02	FATE	2.03	0.24	5.59	6329
2026-11-03	FATE	2.05	0.24	0.00	6411
2026-11-04	FATE	2.1	0.24	20.00	6405
2026-11-05	FATE	1.86	0.24	51.00	6388
2026-11-06	FATE	1.84	0.23	0.49	6381
2026-11-09	FATE	1.94	0.23	10.94	6382
2026-11-10	FATE	1.77	0.35	42.57	7029
2026-11-11	FATE	1.605	0.36	0.42	7079
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-13	FATE	2.00	5.6	-	-1.02
2026-10-14	FATE	1.93	5.6	-	-1.02
2026-10-15	FATE	1.93	5.6	-	-1.02
2026-10-16	FATE	1.79	5.6	-	-1.02
2026-10-19	FATE	1.87	5.6	-	-1.02
2026-10-20	FATE	1.87	5.6	-	-1.02
2026-10-21	FATE	2.05	5.6	-	-1.02
2026-10-22	FATE	2.11	5.6	-	-1.02
2026-10-23	FATE	2.10	5.6	-	-1.02
2026-10-26	FATE	2.06	5.6	-	-1.02
2026-10-27	FATE	2.06	5.6	-	-1.02
2026-10-28	FATE	2.18	5.6	-	-1.02
2026-10-29	FATE	2.18	5.6	-	-1.02
2026-10-30	FATE	2.09	5.6	-	-1.02
2026-11-02	FATE	2.03	5.6	-	-1.02
2026-11-03	FATE	2.05	5.6	-	-1.02
2026-11-04	FATE	2.10	5.6	-	-1.02
2026-11-05	FATE	1.85	5.6	-	-1.02
2026-11-06	FATE	1.84	0.0	-	-1.02
2026-11-09	FATE	1.95	0.0	-	-1.02
2026-11-10	FATE	1.77	0.0	-	-1.02
2026-11-11	FATE	1.60	0.0	-	-1.02
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-13	FATE	-2.39	-1.87	9.42
2026-10-14	FATE	-2.39	-1.87	9.42
2026-10-15	FATE	-2.39	-1.87	9.42
2026-10-16	FATE	-2.39	-1.87	9.42
2026-10-19	FATE	-2.39	-2.02	9.42
2026-10-20	FATE	-2.39	-2.02	9.42
2026-10-21	FATE	-2.39	-2.02	9.42
2026-10-22	FATE	-2.39	-2.02	9.42
2026-10-23	FATE	-2.39	-2.02	9.42
2026-10-26	FATE	-2.39	-0.94	9.42
2026-10-27	FATE	-2.39	-0.94	9.30
2026-10-28	FATE	-2.39	-0.94	9.30
2026-10-29	FATE	-2.39	-0.94	9.30
2026-10-30	FATE	-2.39	-0.94	9.30
2026-11-02	FATE	-2.39	-1.07	9.30
2026-11-03	FATE	-2.39	-1.07	9.30
2026-11-05	FATE	-2.51	-1.07	9.30
2026-11-06	FATE	-2.51	-1.07	9.30
2026-11-09	FATE	-2.47	-1.78	9.16
2026-11-10	FATE	-2.47	-1.78	9.16
2026-11-11	FATE	-2.47	-1.78	8.60
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.25

Avg. EPS Est. Current Quarter

-0.27

Avg. EPS Est. Next Quarter

-0.28

Insider Transactions

-2.47

Institutional Transactions

-1.78

Beta

2.68

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

97.6

Max Drawdown 5-Year %

-98.9

Target Price

5.56

P/E

Forward P/E

PEG

P/S

41.08

P/B

1.47

P/Free Cash Flow

EPS

-1.03

Average EPS Est. Cur. Y

-1.02

EPS Next Y. (Est.)

-0.97

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2619.64

Relative Volume

1.81

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ FATE Healthcare

$1.61

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

15/25

Volume

3/15

Valuation

12/20

TP/AR

3/10

Options

8/10

RSI

30.6

Range 1M

0.8%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

7/30

Estimates

2/20

Inst/Vol

4/15

Options

8/10

EPS Yr

11.1%

EPS NY

-1.8%

52W%

28.7%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +245.3% upside

Quality

2/30

Valuation

16/30

Growth

8/25

Stability

4/10

LT Trend

4/5

Upside

+245.3%

Quality

FATE — P/E HistoricalBiotechnology

Fate Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 161

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

FATE

Latest News

—

Caricamento notizie per FATE…

stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today

news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance

stock history FATE – Fate Therapeutics, Inc. invest stock market

stock prices FATE premarket after hours

ticker FATE fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: FATE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y